Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ViSER1: Viramidine vs Ribavirin in Treatment-Naive Chronic Hepatitis C
NCT00230958Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Dec 2003
- Primary completion
- Jan 2006
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 3, randomised, double-blind trial of taribavirin in hepatitis C (HCV) (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoints: Undetectable plasma HCV RNA at 24-week post-treatment follow-up and Proportion of patients with hemoglobin less than 10 g/dL or >2.5 g/dL drop. Started Dec 2003; status: completed.
02
Drugs
taribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00230958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230958.